PlainPharmaWatch

CMS Open Payments · Tool

KARL STORZ Endoscopy-America vs ABK Biomedical USA, Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

ABK Biomedical USA, Inc. has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,409, versus 655 for the other company. Its single largest recorded recipient represents 33.6% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

KARL STORZ Endoscopy-America
HHI 655 · top recipient 19.6%
Ranked #1,194 of 1,838 companies by HHI
ABK Biomedical USA, Inc.
HHI 1,409 · top recipient 33.6%
Ranked #895 of 1,838 companies by HHI

Payment Overview

Total Payments
$1.7M
% of Industry
0.0%
Transactions
1,632
Avg per Transaction
$1.0K
Recipients
1,585
Avg per Recipient
$1.0K
Payment Types
9
Top Payment Type
Education
Total Payments
$1.6M
% of Industry
0.0%
Transactions
459
Avg per Transaction
$3.6K
Recipients
49
Avg per Recipient
$33.6K
Payment Types
2
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

KARL STORZ Endoscopy-America vs ABK Biomedical USA, Inc. - total reported payments in CMS Open Payments PY2024

KARL STORZ Endoscopy-America$1.7MABK Biomedical USA, Inc.$1.6M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

KARL STORZ Endoscopy-America

Education $622.8K

44.9%

Debt Forgiveness $382.5K

27.6%

Consulting Fee $153.2K

11.0%

Grant $146.8K

10.6%

Food and Beverage $37.7K

2.7%

Travel and Lodging $28.7K

2.1%

ABK Biomedical USA, Inc.

Food and Beverage $4.4K

66.4%

Consulting Fee $2.2K

33.6%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

KARL STORZ Endoscopy-America

  1. 1

    Riverside Methodist Hospital

    $271,720.70 · 6 txns

  2. 2

    Massachusetts Eye And Ear Infirmary

    $97,118.95 · 11 txns

  3. 3

    Uci Medical Center

    $94,484.21 · 50 txns

  4. 4

    University Of Washington Med Ctr

    $89,371.26 · 75 txns

  5. 5

    Nationwide Childrens Hospital

    $84,094.05 · 71 txns

ABK Biomedical USA, Inc.

  1. 1

    MATTHEW NIEMEYER

    $2,200.00 · 2 txns

  2. 2

    NADINE ABI-JAOUDEH

    $530.19 · 5 txns

  3. 3

    Eric Wang

    $410.67 · 7 txns

  4. 4

    JEREMY KIM

    $386.36 · 6 txns

  5. 5

    RAVI SHRIDHAR

    $317.19 · 6 txns

Summary Comparison

Metric KARL STORZ Endoscopy-America ABK Biomedical USA, Inc.
Total Payments $1.7M $1.6M
% of Industry Total 0.0% 0.0%
Transaction Count 1,632 459
Avg per Transaction $1.0K $3.6K
Recipient Count 1,585 49
Avg per Recipient $1.0K $33.6K
Payment Type Count 9 2
Top Payment Type Education Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.